三药联合吸入慢性阻塞性肺疾病32例疗效观察被引量：2

下载PDF

导出

摘要目的:观察联合吸入噻托溴铵和布地奈德(雷诺考特)/福莫特罗干粉剂对稳定期、Ⅲ～Ⅳ级的慢性阻塞性肺疾病(COPD)患者的临床疗效。方法:采用自身对照研究方法,32例常规吸入布地奈得福莫特罗干粉吸入剂(160/4.5μg)维持治疗6个月以上的重度COPD患者联合吸入噻托溴铵干粉胶囊18μg,1次/d。疗程6个月,观察前后进行肺功能指标测定和StGeorges呼吸问卷(SGRQ)生活质量评分比较。结果:患者治疗后1、3、6个月患者FEV1、PEF、FVC较观察前均有不同程度的提高(P<0.05);呼吸问卷生活质量评分比观察前明显减少(P<0.05)。结论:联合吸入噻托溴铵和布地奈德/福莫特罗干粉剂能够改善稳定期Ⅲ-Ⅳ级COPD患者的肺功能和生活质量。

作者韩元岭徐丽娜

机构地区黑龙江省宝泉岭分局中心医院呼吸内科

出处《航空航天医学杂志》 2011年第7期847-848,共2页 Journal of Aerospace medicine

关键词慢性阻塞性肺疾病噻托溴铵布地奈德/福莫特罗干粉吸入剂肺功能

分类号 R563 [医药卫生—呼吸系统]

引文网络
相关文献

参考文献6

1郑劲平,康健,蔡柏蔷,周新,曹兆龙,白春学,钟南山.吸入噻托溴铵干粉与异丙托溴铵定量气雾剂治疗慢性阻塞性肺疾病的疗效与安全性比较[J].中华结核和呼吸杂志,2006,29(6):363-367. 被引量：158
2慢性阻塞性肺疾病诊治指南[J].中华结核和呼吸杂志,2002,25(8):453-460. 被引量：5103
3Vincken W,van Noord JA,Greefhorst AP,et al.Improved health outcomes in patients with COPD during 1 year’s treatment with tiotropium. European Respiratory Journal . 2002
4Wijkstra PJ,TenVergert EM,Altena RV,et al.Reliability and validity of the chronic respiratory questionnaire(CRQ). Thorax . 1994
5Rutten-van Molken,M.,Roos,B.,Van,Noord,J. A.An empirical comparison of the St George’s Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax . 1999
6O′Donnell DE,Magnussen H,Aguilaniu B,et al.Tiotropiu M i mproves exercise tolerance in COPD. American Journal of Respiratory and Critical Care Medicine . 2002

二级参考文献11

1刘升明,王小平,王大礼,周玉民,吕嘉春,郑劲平,钟南山,冉丕鑫.广东部分地区慢性阻塞性肺疾病发病状况调查[J].中华医学杂志,2005,85(11):747-752. 被引量：150
2Barnes PJ,Stockley RA.COPD:current therapeutic interventions and future approaches.Eur Respir J,2005,25:1084-1106.
3Disse B,Reichl R,Speck G,et al.Ba 679 BR,a novel long-acting anticholinergic bronchodilator.Life Sci,1993,52:537-544.
4Takahashi T,Belvisi MG,Patel H,et al.Effect of Ba 679 BR,a novel long-acting anticholinergic agent,on cholinergic neurotransmission in guinea pig and human airways.Am J Respir Crit Care Med,1994,150(6 Pt 1):1640-1645.
52003 Update:Workshop Report,Global Strategy for Diagnosis,Management,and Prevention of COPD.National Heart,Lung,and Blood Institute and World Health Organization,Global initiative for chronic obstructive lung disease (GOLD).Available from:http://www.goldeopd.org/
6Casaburi R,Mahler DA,Jones PW,et al.A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.Eur Respir J,2002,19:217-224.
7Littner MR,Ilowite JS,Tashkin DP,et al.Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease.Am J Respir Crit Care Med,2000,161 (4 Pt 1):1136-1142.
8Casaburi R,Briggs DD Jr,Donohue JF,et al.The spirometric efficacy of once-daily dosing with tiotropium in stable COPD:a 13-week multicenter trial.The US Tiotropium Study Group.Chest,2000,118:1294-1302.
9O'Donnell DE,Fluge T,Gerken F,et al.Effects of tiotropium on lung hyperinflation,dyspnoea and exercise tolerance in COPD.Eur Respir J,2004,23:832-840.
10Maltais F,Hamilton A,Marciniuk D,et al.Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD.Chest,2005,128:1168-1178.